A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects.
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ramelteon (Primary)
- Indications Alzheimer's disease; Sleep disorders
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 23 Jan 2009 Official Title amended as reported by ClinicalTrials.gov.
- 17 Jul 2008 New trial record.